Cancer in ANCA-Associated Glomerulonephritis: A Registry-Based Cohort Study
Table 3
Studies on cancer incidence in patients with AAV.
Characteristic
Heijl et al. (2011)
Zycinska et al. (2013)
Rahmattulla et al. (2015)
Van Daalen et al. (2016)
This study
Total
Study period
1995–2007
1990–2008
1991–2013
2000–2014
1988–2012
Number of patients
535
117
138
323
419
1532
Cumulative person-years
2650
NR
1339
1802
3010
8801
Number of observed cancers
50
15
85
45
41
236
Number of expected cancers
31.7
23.8
37.5
137.5
SIR (95% CI)
1.58 (1.17 to 2.08)
2.50 (1.20 to 2.90)
2.21 (1.64 to 2.92)
1.89 (1.38 to 2.53)
1.09 (0.81 to 1.49)
1.72 (1.51 to 1.95)
All non-NMSC sites
Number of observed cancers
35
24
20
34
122
Number of expected cancers
25.9
18.33
35.4
100.8
SIR (95% CI)
1.30 (0.90 to 1.80)
(0.97 to 3.57)
1.46 (0.93 to 2.17)
1.09 (0.67 to 1.69)
0.96 (0.69 to 1.34)
1.21 (1.01 to 1.45)
Not reported; calculated by the authors of this study; SIR, standardised incidence ratio; 95% CI, 95% confidence interval; NR, not reported; NMSC, nonmelanoma skin cancer.
